ID   ALDOA_HUMAN             Reviewed;         364 AA.
AC   P04075; B4DXI7; Q6FH76; Q6FI10; Q96B15; Q9BWD9; Q9UCN2;
DT   01-NOV-1986, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   10-MAY-2017, entry version 208.
DE   RecName: Full=Fructose-bisphosphate aldolase A;
DE            EC=4.1.2.13;
DE   AltName: Full=Lung cancer antigen NY-LU-1;
DE   AltName: Full=Muscle-type aldolase;
GN   Name=ALDOA; Synonyms=ALDA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=3840020; DOI=10.1016/0006-291X(85)91818-2;
RA   Sakakibara M., Mukai T., Hori K.;
RT   "Nucleotide sequence of a cDNA clone for human aldolase: a messenger
RT   RNA in the liver.";
RL   Biochem. Biophys. Res. Commun. 131:413-420(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fibroblast;
RX   PubMed=3030757; DOI=10.1111/j.1432-1033.1987.tb10984.x;
RA   Izzo P., Costanzo P., Lupo A., Rippa E., Borghese A.M., Paolella G.,
RA   Salvatore F.;
RT   "A new human species of aldolase A mRNA from fibroblasts.";
RL   Eur. J. Biochem. 164:9-13(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3391172; DOI=10.1111/j.1432-1033.1988.tb14136.x;
RA   Izzo P., Costanzo P., Lupo A., Rippa E., Paolella G., Salvatore F.;
RT   "Human aldolase A gene. Structural organization and tissue-specific
RT   expression by multiple promoters and alternate mRNA processing.";
RL   Eur. J. Biochem. 174:569-578(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1999195; DOI=10.1111/j.1432-1033.1991.tb15766.x;
RA   Mukai T., Arai Y., Yatsuki H., Joh K., Hori K.;
RT   "An additional promoter functions in the human aldolase A gene, but
RT   not in rat.";
RL   Eur. J. Biochem. 195:781-787(1991).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S.,
RA   Neubert P., Kstrang K., Schatten R., Shen B., Henze S., Mar W.,
RA   Korn B., Zuo D., Hu Y., LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Cervix, Eye, Lung, Testis, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-108 (ISOFORM 1).
RX   PubMed=3441006; DOI=10.1016/0022-2836(87)90556-0;
RA   Maire P., Gautron S., Hakim V., Gregori C., Mennecier F., Kahn A.;
RT   "Characterization of three optional promoters in the 5' region of the
RT   human aldolase A gene.";
RL   J. Mol. Biol. 197:425-438(1987).
RN   [11]
RP   PROTEIN SEQUENCE OF 2-364.
RX   PubMed=3355497; DOI=10.1042/bj2490779;
RA   Freemont P.S., Dunbar B., Fothergill-Gilmore L.A.;
RT   "The complete amino acid sequence of human skeletal-muscle fructose-
RT   bisphosphate aldolase.";
RL   Biochem. J. 249:779-788(1988).
RN   [12]
RP   PROTEIN SEQUENCE OF 2-63 AND 148-358.
RX   PubMed=6696436; DOI=10.1016/0003-9861(84)90075-4;
RA   Freemont P.S., Dunbar B., Fothergill L.A.;
RT   "Human skeletal-muscle aldolase: N-terminal sequence analysis of CNBr-
RT   and o-iodosobenzoic acid-cleavage fragments.";
RL   Arch. Biochem. Biophys. 228:342-352(1984).
RN   [13]
RP   PROTEIN SEQUENCE OF 2-22.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [14]
RP   PROTEIN SEQUENCE OF 2-16.
RC   TISSUE=Colon carcinoma;
RX   PubMed=1353685; DOI=10.1016/0167-4889(92)90078-P;
RA   Lee K.N., Maxwell M.D., Patterson M.K. Jr., Birckbichler P.J.,
RA   Conway E.;
RT   "Identification of transglutaminase substrates in HT29 colon cancer
RT   cells: use of 5-(biotinamido)pentylamine as a transglutaminase-
RT   specific probe.";
RL   Biochim. Biophys. Acta 1136:12-16(1992).
RN   [15]
RP   PROTEIN SEQUENCE OF 2-13; 29-42; 44-56; 61-69; 88-99; 154-173; 244-258
RP   AND 332-342, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 139-364 (ISOFORM 1/2).
RX   PubMed=3674018;
RA   Tolan D.R., Niclas J., Bruce B.D., Lebo R.V.;
RT   "Evolutionary implications of the human aldolase-A, -B, -C, and -
RT   pseudogene chromosome locations.";
RL   Am. J. Hum. Genet. 41:907-924(1987).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-46, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   INTERACTION WITH FBP2.
RX   PubMed=18214967; DOI=10.1002/prot.21909;
RA   Gizak A., Maciaszczyk E., Dzugaj A., Eschrich K., Rakus D.;
RT   "Evolutionary conserved N-terminal region of human muscle fructose
RT   1,6-bisphosphatase regulates its activity and the interaction with
RT   aldolase.";
RL   Proteins 72:209-216(2008).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36 AND SER-39, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [22]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-42; LYS-108 AND LYS-330, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36 AND SER-39, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   MALONYLATION AT LYS-111 AND LYS-312.
RX   PubMed=21908771; DOI=10.1074/mcp.M111.012658;
RA   Peng C., Lu Z., Xie Z., Cheng Z., Chen Y., Tan M., Luo H., Zhang Y.,
RA   He W., Yang K., Zwaans B.M., Tishkoff D., Ho L., Lombard D., He T.C.,
RA   Dai J., Verdin E., Ye Y., Zhao Y.;
RT   "The first identification of lysine malonylation substrates and its
RT   regulatory enzyme.";
RL   Mol. Cell. Proteomics 10:M111.012658.01-M111.012658.12(2011).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-39 AND SER-46, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S.,
RA   Fischer-Posovszky P., Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion
RT   profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [28]
RP   CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE ANALYSIS], AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-9; SER-36; SER-39 AND
RP   SER-46, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-39; SER-46 AND SER-272,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [33]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-42, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).
RX   PubMed=2335208; DOI=10.1016/0014-5793(90)80211-Z;
RA   Gamblin S.J., Cooper B., Millar J.R., Davies G.J., Littlechild J.A.,
RA   Watson H.C.;
RT   "The crystal structure of human muscle aldolase at 3.0-A resolution.";
RL   FEBS Lett. 262:282-286(1990).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS).
RX   PubMed=2056525; DOI=10.1016/0022-2836(91)90650-U;
RA   Gamblin S.J., Davies G.J., Grimes J.M., Jackson R.M.,
RA   Littlechild J.A., Watson H.C.;
RT   "Activity and specificity of human aldolases.";
RL   J. Mol. Biol. 219:573-576(1991).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS).
RX   PubMed=10048322; DOI=10.1110/ps.8.2.291;
RA   Dalby A., Dauter Z., Littlechild J.A.;
RT   "Crystal structure of human muscle aldolase complexed with fructose
RT   1,6-bisphosphate: mechanistic implications.";
RL   Protein Sci. 8:291-297(1999).
RN   [38]
RP   VARIANT GSD12 GLY-129, AND CHARACTERIZATION OF VARIANT GSD12 GLY-129.
RX   PubMed=2825199; DOI=10.1073/pnas.84.23.8623;
RA   Kishi H., Mukai T., Hirono A., Fujii H., Miwa S., Hori K.;
RT   "Human aldolase A deficiency associated with a hemolytic anemia:
RT   thermolabile aldolase due to a single base mutation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:8623-8627(1987).
RN   [39]
RP   CHARACTERIZATION OF VARIANT GSD12 GLY-129.
RX   PubMed=2229018; DOI=10.1093/oxfordjournals.jbchem.a123174;
RA   Takasaki Y., Takahashi I., Mukai T., Hori K.;
RT   "Human aldolase A of a hemolytic anemia patient with Asp-128-->Gly
RT   substitution: characteristics of an enzyme generated in E. coli
RT   transfected with the expression plasmid pHAAD128G.";
RL   J. Biochem. 108:153-157(1990).
RN   [40]
RP   VARIANT GSD12 LYS-207.
RX   PubMed=8598869; DOI=10.1056/NEJM199604253341705;
RA   Kreuder J., Borkhardt A., Repp R., Pekrun A., Goettsche B.,
RA   Gottschalk U., Reichmann H., Schachenmayr W., Schlegel K., Lampert F.;
RT   "Brief report: inherited metabolic myopathy and hemolysis due to a
RT   mutation in aldolase A.";
RL   N. Engl. J. Med. 334:1100-1104(1996).
RN   [41]
RP   VARIANT GSD12 TYR-339.
RX   PubMed=14615364; DOI=10.1182/blood-2003-09-3160;
RA   Yao D.C., Tolan D.R., Murray M.F., Harris D.J., Darras B.T., Geva A.,
RA   Neufeld E.J.;
RT   "Hemolytic anemia and severe rhabdomyolysis caused by compound
RT   heterozygous mutations of the gene for erythrocyte/muscle isozyme of
RT   aldolase, ALDOA(Arg303X/Cys338Tyr).";
RL   Blood 103:2401-2403(2004).
RN   [42]
RP   VARIANT GSD12 SER-347, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   CHARACTERIZATION OF VARIANTS GSD12 LYS-207 AND SER-347.
RX   PubMed=14766013; DOI=10.1042/BJ20031941;
RA   Esposito G., Vitagliano L., Costanzo P., Borrelli L., Barone R.,
RA   Pavone L., Izzo P., Zagari A., Salvatore F.;
RT   "Human aldolase A natural mutants: relationship between flexibility of
RT   the C-terminal region and enzyme function.";
RL   Biochem. J. 380:51-56(2004).
CC   -!- FUNCTION: Plays a key role in glycolysis and gluconeogenesis. In
CC       addition, may also function as scaffolding protein (By
CC       similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: D-fructose 1,6-bisphosphate = glycerone
CC       phosphate + D-glyceraldehyde 3-phosphate.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=52 uM for fructose 1,6-bisphosphate (at 30 degrees Celsius)
CC         {ECO:0000269|PubMed:14766013};
CC       Temperature dependence:
CC         Thermal denaturation midpoint (Tm) is 54.4 degrees Celsius.
CC         {ECO:0000269|PubMed:14766013};
CC   -!- PATHWAY: Carbohydrate degradation; glycolysis; D-glyceraldehyde 3-
CC       phosphate and glycerone phosphate from D-glucose: step 4/4.
CC   -!- SUBUNIT: Homotetramer. Interacts with SNX9 and WAS (By
CC       similarity). Interacts with FBP2; the interaction blocks FBP2
CC       inhibition by physiological concentrations of AMP and reduces
CC       inhibition by Ca(2+). {ECO:0000250, ECO:0000269|PubMed:18214967}.
CC   -!- INTERACTION:
CC       P09972:ALDOC; NbExp=6; IntAct=EBI-10194102, EBI-2952751;
CC       P05014:IFNA4; NbExp=3; IntAct=EBI-10194102, EBI-10194381;
CC       P12004:PCNA; NbExp=3; IntAct=EBI-709613, EBI-358311;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, myofibril, sarcomere, I band.
CC       Cytoplasm, myofibril, sarcomere, M line. Note=In skeletal muscle,
CC       accumulates around the M line and within the I band, colocalizing
CC       with FBP2 on both sides of the Z line in the absence of Ca(2+).
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P04075-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P04075-2; Sequence=VSP_047261;
CC   -!- DISEASE: Glycogen storage disease 12 (GSD12) [MIM:611881]: A
CC       metabolic disorder associated with increased hepatic glycogen and
CC       hemolytic anemia. It may lead to myopathy with exercise
CC       intolerance and rhabdomyolysis. {ECO:0000269|PubMed:14615364,
CC       ECO:0000269|PubMed:14766013, ECO:0000269|PubMed:2229018,
CC       ECO:0000269|PubMed:2825199, ECO:0000269|PubMed:8598869}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- MISCELLANEOUS: In vertebrates, three forms of this ubiquitous
CC       glycolytic enzyme are found, aldolase A in muscle, aldolase B in
CC       liver and aldolase C in brain.
CC   -!- SIMILARITY: Belongs to the class I fructose-bisphosphate aldolase
CC       family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M11560; AAA51690.1; -; mRNA.
DR   EMBL; X05236; CAA28861.1; -; mRNA.
DR   EMBL; X12447; CAA30979.1; -; Genomic_DNA.
DR   EMBL; AK301993; BAG63399.1; -; mRNA.
DR   EMBL; CR536528; CAG38765.1; -; mRNA.
DR   EMBL; CR541880; CAG46678.1; -; mRNA.
DR   EMBL; AC093512; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471238; EAW79933.1; -; Genomic_DNA.
DR   EMBL; BC000367; AAH00367.2; -; mRNA.
DR   EMBL; BC004333; AAH04333.1; -; mRNA.
DR   EMBL; BC010660; AAH10660.1; -; mRNA.
DR   EMBL; BC012880; AAH12880.1; -; mRNA.
DR   EMBL; BC013614; AAH13614.1; -; mRNA.
DR   EMBL; BC015888; AAH15888.1; -; mRNA.
DR   EMBL; BC016170; AAH16170.1; -; mRNA.
DR   EMBL; BC016800; AAH16800.1; -; mRNA.
DR   EMBL; M21190; AAA51697.1; -; mRNA.
DR   CCDS; CCDS10668.1; -. [P04075-1]
DR   CCDS; CCDS58450.1; -. [P04075-2]
DR   PIR; S14084; ADHUA.
DR   RefSeq; NP_000025.1; NM_000034.3. [P04075-1]
DR   RefSeq; NP_001121089.1; NM_001127617.2. [P04075-1]
DR   RefSeq; NP_001230106.1; NM_001243177.1. [P04075-2]
DR   RefSeq; NP_908930.1; NM_184041.2. [P04075-1]
DR   RefSeq; NP_908932.1; NM_184043.2. [P04075-1]
DR   RefSeq; XP_011544070.1; XM_011545768.2. [P04075-1]
DR   UniGene; Hs.513490; -.
DR   UniGene; Hs.732822; -.
DR   PDB; 1ALD; X-ray; 2.00 A; A=2-364.
DR   PDB; 2ALD; X-ray; 2.10 A; A=2-364.
DR   PDB; 4ALD; X-ray; 2.80 A; A=2-364.
DR   PDBsum; 1ALD; -.
DR   PDBsum; 2ALD; -.
DR   PDBsum; 4ALD; -.
DR   ProteinModelPortal; P04075; -.
DR   SMR; P04075; -.
DR   BioGrid; 106728; 111.
DR   IntAct; P04075; 37.
DR   MINT; MINT-4998828; -.
DR   STRING; 9606.ENSP00000336927; -.
DR   ChEMBL; CHEMBL2106; -.
DR   DrugBank; DB08240; N-(4-CHLOROPHENYL)-3-(PHOSPHONOOXY)NAPHTHALENE-2-CARBOXAMIDE.
DR   iPTMnet; P04075; -.
DR   PhosphoSitePlus; P04075; -.
DR   SwissPalm; P04075; -.
DR   BioMuta; ALDOA; -.
DR   DMDM; 113606; -.
DR   DOSAC-COBS-2DPAGE; P04075; -.
DR   OGP; P04075; -.
DR   REPRODUCTION-2DPAGE; IPI00465439; -.
DR   REPRODUCTION-2DPAGE; P04075; -.
DR   SWISS-2DPAGE; P04075; -.
DR   UCD-2DPAGE; P04075; -.
DR   EPD; P04075; -.
DR   PaxDb; P04075; -.
DR   PeptideAtlas; P04075; -.
DR   PRIDE; P04075; -.
DR   TopDownProteomics; P04075-1; -. [P04075-1]
DR   DNASU; 226; -.
DR   Ensembl; ENST00000338110; ENSP00000336927; ENSG00000149925. [P04075-1]
DR   Ensembl; ENST00000395248; ENSP00000378669; ENSG00000149925. [P04075-2]
DR   Ensembl; ENST00000412304; ENSP00000400452; ENSG00000149925. [P04075-1]
DR   Ensembl; ENST00000563060; ENSP00000455800; ENSG00000149925. [P04075-1]
DR   Ensembl; ENST00000564546; ENSP00000455917; ENSG00000149925. [P04075-1]
DR   Ensembl; ENST00000564595; ENSP00000457468; ENSG00000149925. [P04075-2]
DR   Ensembl; ENST00000566897; ENSP00000455724; ENSG00000149925. [P04075-1]
DR   Ensembl; ENST00000569545; ENSP00000455700; ENSG00000149925. [P04075-1]
DR   GeneID; 226; -.
DR   KEGG; hsa:226; -.
DR   UCSC; uc010veg.3; human. [P04075-1]
DR   CTD; 226; -.
DR   DisGeNET; 226; -.
DR   GeneCards; ALDOA; -.
DR   HGNC; HGNC:414; ALDOA.
DR   HPA; CAB006252; -.
DR   HPA; HPA004177; -.
DR   MalaCards; ALDOA; -.
DR   MIM; 103850; gene.
DR   MIM; 611881; phenotype.
DR   neXtProt; NX_P04075; -.
DR   OpenTargets; ENSG00000149925; -.
DR   Orphanet; 57; Glycogen storage disease due to aldolase A deficiency.
DR   PharmGKB; PA24707; -.
DR   eggNOG; KOG1557; Eukaryota.
DR   eggNOG; COG3588; LUCA.
DR   GeneTree; ENSGT00390000010235; -.
DR   HOVERGEN; HBG002386; -.
DR   InParanoid; P04075; -.
DR   KO; K01623; -.
DR   OMA; PNMVIDG; -.
DR   OrthoDB; EOG091G0A9T; -.
DR   PhylomeDB; P04075; -.
DR   TreeFam; TF314203; -.
DR   BioCyc; MetaCyc:HS07647-MONOMER; -.
DR   BRENDA; 4.1.2.13; 2681.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-70171; Glycolysis.
DR   Reactome; R-HSA-70263; Gluconeogenesis.
DR   SABIO-RK; P04075; -.
DR   UniPathway; UPA00109; UER00183.
DR   EvolutionaryTrace; P04075; -.
DR   GeneWiki; Aldolase_A; -.
DR   GenomeRNAi; 226; -.
DR   PRO; PR:P04075; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000149925; -.
DR   CleanEx; HS_ALDOA; -.
DR   ExpressionAtlas; P04075; baseline and differential.
DR   Genevisible; P04075; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0031674; C:I band; TAS:BHF-UCL.
DR   GO; GO:0031430; C:M band; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:1904724; C:tertiary granule lumen; TAS:Reactome.
DR   GO; GO:0003779; F:actin binding; TAS:BHF-UCL.
DR   GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
DR   GO; GO:0008092; F:cytoskeletal protein binding; IDA:BHF-UCL.
DR   GO; GO:0070061; F:fructose binding; IDA:BHF-UCL.
DR   GO; GO:0004332; F:fructose-bisphosphate aldolase activity; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0015631; F:tubulin binding; TAS:BHF-UCL.
DR   GO; GO:0007015; P:actin filament organization; TAS:BHF-UCL.
DR   GO; GO:0006754; P:ATP biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0061621; P:canonical glycolysis; TAS:Reactome.
DR   GO; GO:0030388; P:fructose 1,6-bisphosphate metabolic process; IDA:BHF-UCL.
DR   GO; GO:0006000; P:fructose metabolic process; IMP:BHF-UCL.
DR   GO; GO:0006094; P:gluconeogenesis; TAS:Reactome.
DR   GO; GO:0006096; P:glycolytic process; IMP:BHF-UCL.
DR   GO; GO:0046716; P:muscle cell cellular homeostasis; IMP:BHF-UCL.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0051289; P:protein homotetramerization; ISS:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IDA:BHF-UCL.
DR   GO; GO:0006941; P:striated muscle contraction; IMP:BHF-UCL.
DR   Gene3D; 3.20.20.70; -; 1.
DR   InterPro; IPR029768; Aldolase_I_AS.
DR   InterPro; IPR013785; Aldolase_TIM.
DR   InterPro; IPR000741; FBA_I.
DR   Pfam; PF00274; Glycolytic; 1.
DR   PROSITE; PS00158; ALDOLASE_CLASS_I; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Disease mutation;
KW   Glycogen storage disease; Glycolysis; Hereditary hemolytic anemia;
KW   Isopeptide bond; Lyase; Phosphoprotein; Polymorphism;
KW   Reference proteome; Schiff base; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22223895,
FT                                ECO:0000269|PubMed:12665801,
FT                                ECO:0000269|PubMed:1353685,
FT                                ECO:0000269|PubMed:3355497,
FT                                ECO:0000269|PubMed:6696436,
FT                                ECO:0000269|Ref.15}.
FT   CHAIN         2    364       Fructose-bisphosphate aldolase A.
FT                                /FTId=PRO_0000216936.
FT   ACT_SITE    188    188       Proton acceptor. {ECO:0000250}.
FT   ACT_SITE    230    230       Schiff-base intermediate with
FT                                dihydroxyacetone-P.
FT   BINDING      56     56       Substrate.
FT   BINDING     147    147       Substrate.
FT   SITE        364    364       Necessary for preference for fructose
FT                                1,6-bisphosphate over fructose 1-
FT                                phosphate.
FT   MOD_RES       5      5       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P05065}.
FT   MOD_RES       9      9       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      36     36       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      39     39       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES      42     42       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      46     46       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     108    108       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     111    111       N6-malonyllysine.
FT                                {ECO:0000269|PubMed:21908771}.
FT   MOD_RES     132    132       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P05065}.
FT   MOD_RES     272    272       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     312    312       N6-malonyllysine.
FT                                {ECO:0000269|PubMed:21908771}.
FT   MOD_RES     330    330       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   CROSSLNK     42     42       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1);
FT                                alternate. {ECO:0000244|PubMed:25114211}.
FT   CROSSLNK     42     42       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2);
FT                                alternate. {ECO:0000244|PubMed:25114211}.
FT   VAR_SEQ       1      1       M -> MARRKPEGSSFNMTHLSMAMAFSFPPVASGQLHPQL
FT                                GNTQHQTELGKELATTSTM (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_047261.
FT   VARIANT      82     82       E -> Q (in dbSNP:rs11553107).
FT                                /FTId=VAR_048219.
FT   VARIANT     129    129       D -> G (in GSD12; thermolabile;
FT                                dbSNP:rs121909533).
FT                                {ECO:0000269|PubMed:2229018,
FT                                ECO:0000269|PubMed:2825199}.
FT                                /FTId=VAR_000550.
FT   VARIANT     142    142       G -> V (in dbSNP:rs11553108).
FT                                /FTId=VAR_048220.
FT   VARIANT     207    207       E -> K (in GSD12; reduces thermal
FT                                stability; 3-fold decrease in catalytic
FT                                efficiency mostly due to reduced
FT                                substrate affinity; dbSNP:rs121909534).
FT                                {ECO:0000269|PubMed:14766013,
FT                                ECO:0000269|PubMed:8598869}.
FT                                /FTId=VAR_044142.
FT   VARIANT     339    339       C -> Y (in GSD12).
FT                                {ECO:0000269|PubMed:14615364}.
FT                                /FTId=VAR_044143.
FT   VARIANT     347    347       G -> S (in GSD12; does not affect thermal
FT                                stability; 4-fold decrease in catalytic
FT                                efficiency due to reduced enzyme
FT                                activity; dbSNP:rs138824667).
FT                                {ECO:0000269|PubMed:14766013}.
FT                                /FTId=VAR_044144.
FT   CONFLICT     73     73       C -> G (in Ref. 3; CAA30979).
FT                                {ECO:0000305}.
FT   CONFLICT    180    180       Q -> R (in Ref. 6; CAG46678).
FT                                {ECO:0000305}.
FT   CONFLICT    196    196       D -> A (in Ref. 3; CAA30979).
FT                                {ECO:0000305}.
FT   CONFLICT    230    230       K -> N (in Ref. 3; CAA30979).
FT                                {ECO:0000305}.
FT   CONFLICT    280    280       A -> S (in Ref. 3; CAA30979).
FT                                {ECO:0000305}.
FT   HELIX        10     23       {ECO:0000244|PDB:1ALD}.
FT   STRAND       29     33       {ECO:0000244|PDB:1ALD}.
FT   HELIX        37     46       {ECO:0000244|PDB:1ALD}.
FT   HELIX        53     64       {ECO:0000244|PDB:1ALD}.
FT   HELIX        68     73       {ECO:0000244|PDB:1ALD}.
FT   STRAND       74     79       {ECO:0000244|PDB:1ALD}.
FT   HELIX        83     85       {ECO:0000244|PDB:1ALD}.
FT   HELIX        94    100       {ECO:0000244|PDB:1ALD}.
FT   STRAND      104    108       {ECO:0000244|PDB:1ALD}.
FT   STRAND      113    115       {ECO:0000244|PDB:1ALD}.
FT   STRAND      119    121       {ECO:0000244|PDB:1ALD}.
FT   STRAND      123    125       {ECO:0000244|PDB:1ALD}.
FT   HELIX       131    140       {ECO:0000244|PDB:1ALD}.
FT   STRAND      145    152       {ECO:0000244|PDB:1ALD}.
FT   STRAND      155    157       {ECO:0000244|PDB:2ALD}.
FT   HELIX       161    179       {ECO:0000244|PDB:1ALD}.
FT   TURN        180    182       {ECO:0000244|PDB:1ALD}.
FT   STRAND      184    191       {ECO:0000244|PDB:1ALD}.
FT   HELIX       199    219       {ECO:0000244|PDB:1ALD}.
FT   HELIX       224    226       {ECO:0000244|PDB:1ALD}.
FT   HELIX       246    258       {ECO:0000244|PDB:1ALD}.
FT   STRAND      267    270       {ECO:0000244|PDB:1ALD}.
FT   HELIX       277    289       {ECO:0000244|PDB:1ALD}.
FT   STRAND      296    303       {ECO:0000244|PDB:1ALD}.
FT   HELIX       304    314       {ECO:0000244|PDB:1ALD}.
FT   HELIX       318    320       {ECO:0000244|PDB:1ALD}.
FT   HELIX       321    338       {ECO:0000244|PDB:1ALD}.
FT   TURN        339    341       {ECO:0000244|PDB:1ALD}.
FT   STRAND      348    350       {ECO:0000244|PDB:1ALD}.
SQ   SEQUENCE   364 AA;  39420 MW;  0AAED80F755A7BE8 CRC64;
     MPYQYPALTP EQKKELSDIA HRIVAPGKGI LAADESTGSI AKRLQSIGTE NTEENRRFYR
     QLLLTADDRV NPCIGGVILF HETLYQKADD GRPFPQVIKS KGGVVGIKVD KGVVPLAGTN
     GETTTQGLDG LSERCAQYKK DGADFAKWRC VLKIGEHTPS ALAIMENANV LARYASICQQ
     NGIVPIVEPE ILPDGDHDLK RCQYVTEKVL AAVYKALSDH HIYLEGTLLK PNMVTPGHAC
     TQKFSHEEIA MATVTALRRT VPPAVTGITF LSGGQSEEEA SINLNAINKC PLLKPWALTF
     SYGRALQASA LKAWGGKKEN LKAAQEEYVK RALANSLACQ GKYTPSGQAG AAASESLFVS
     NHAY
//
